<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Internet Res</journal-id><journal-id journal-id-type="publisher-id">JMIR</journal-id><journal-title-group><journal-title>Journal of Medical Internet Research</journal-title></journal-title-group><issn pub-type="ppub">1439-4456</issn><issn pub-type="epub">1438-8871</issn><publisher><publisher-name>JMIR Publications Inc.</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23722666</article-id><article-id pub-id-type="pmc">3670725</article-id><article-id pub-id-type="publisher-id">v15i5e106</article-id><article-id pub-id-type="doi">10.2196/jmir.2587</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Cost-Utility Analysis of the EVOLVO Study on Remote Monitoring for Heart Failure Patients With Implantable Defibrillators: Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Eysenbach</surname><given-names>Gunther</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Raatikainen</surname><given-names>Pekka</given-names></name></contrib><contrib contrib-type="reviewer"><name><surname>Boriani</surname><given-names>Giuseppe</given-names></name></contrib></contrib-group><contrib-group><contrib id="contrib1" contrib-type="author" corresp="yes"><name><surname>Zanaboni</surname><given-names>Paolo</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff01">1</xref><address><institution>Norwegian Centre for Integrated Care and Telemedicine</institution><institution>University Hospital of North Norway</institution><addr-line>PO Box 35</addr-line><addr-line>Troms&#x000f8;, N-9038</addr-line><country>Norway</country><phone>47 41409600</phone><fax>47 77754098</fax><email>paolo.zanaboni@telemed.no</email></address></contrib><contrib id="contrib2" contrib-type="author"><name><surname>Landolina</surname><given-names>Maurizio</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib id="contrib3" contrib-type="author"><name><surname>Marzegalli</surname><given-names>Maurizio</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff03">3</xref></contrib><contrib id="contrib4" contrib-type="author"><name><surname>Lunati</surname><given-names>Maurizio</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff04">4</xref></contrib><contrib id="contrib5" contrib-type="author"><name><surname>Perego</surname><given-names>Giovanni B</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff05">5</xref></contrib><contrib id="contrib6" contrib-type="author"><name><surname>Guenzati</surname><given-names>Giuseppe</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff06">6</xref></contrib><contrib id="contrib7" contrib-type="author"><name><surname>Curnis</surname><given-names>Antonio</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff07">7</xref></contrib><contrib id="contrib8" contrib-type="author"><name><surname>Valsecchi</surname><given-names>Sergio</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff08">8</xref></contrib><contrib id="contrib9" contrib-type="author"><name><surname>Borghetti</surname><given-names>Francesca</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff08">8</xref></contrib><contrib id="contrib10" contrib-type="author"><name><surname>Borghi</surname><given-names>Gabriella</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff09">9</xref></contrib><contrib id="contrib11" contrib-type="author"><name><surname>Masella</surname><given-names>Cristina</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff10">10</xref></contrib></contrib-group><aff id="aff01" rid="aff01"><sup>1</sup><institution>Norwegian Centre for Integrated Care and Telemedicine</institution><institution>University Hospital of North Norway</institution><addr-line>Troms&#x000f8;</addr-line><country>Norway</country></aff><aff id="aff02" rid="aff02"><sup>2</sup><institution>Cardiology Department</institution><institution>Fondazione Policlinico S Matteo IRCCS</institution><addr-line>Pavia</addr-line><country>Italy</country></aff><aff id="aff03" rid="aff03"><sup>3</sup><institution>Cardiology Department</institution><institution>S Carlo Borromeo Hospital</institution><addr-line>Milan</addr-line><country>Italy</country></aff><aff id="aff04" rid="aff04"><sup>4</sup><institution>Cardiovascular Department</institution><institution>Niguarda Hospital</institution><addr-line>Milan</addr-line><country>Italy</country></aff><aff id="aff05" rid="aff05"><sup>5</sup><institution>Cardiology Division</institution><institution>Istituto Auxologico S Luca Hospital</institution><addr-line>Milan</addr-line><country>Italy</country></aff><aff id="aff06" rid="aff06"><sup>6</sup><institution>Cardiology Department</institution><institution>S. Carlo Borromeo Hospital</institution><addr-line>Milan</addr-line><country>Italy</country></aff><aff id="aff07" rid="aff07"><sup>7</sup><institution>Cardiology Unit</institution><institution>Ospedali Civili</institution><addr-line>Brescia</addr-line><country>Italy</country></aff><aff id="aff08" rid="aff08"><sup>8</sup><institution>Clinical Department</institution><institution>Medtronic Italia</institution><addr-line>Rome</addr-line><country>Italy</country></aff><aff id="aff09" rid="aff09"><sup>9</sup><institution>CEFRIEL</institution><institution>Regione Lombardia</institution><addr-line>Milan</addr-line><country>Italy</country></aff><aff id="aff10" rid="aff10"><sup>10</sup><institution>Department of Management, Economics and Industrial Engineering</institution><institution>Politecnico di Milano</institution><addr-line>Milan</addr-line><country>Italy</country></aff><author-notes><corresp>Corresponding Author: Paolo Zanaboni <email>paolo.zanaboni@telemed.no</email></corresp></author-notes><pub-date pub-type="collection"><month>5</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>30</day><month>5</month><year>2013</year></pub-date><volume>15</volume><issue>5</issue><elocation-id>e106</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2013</year></date><date date-type="rev-request"><day>21</day><month>3</month><year>2013</year></date><date date-type="rev-recd"><day>25</day><month>4</month><year>2013</year></date><date date-type="accepted"><day>09</day><month>5</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9;Paolo Zanaboni, Maurizio Landolina, Maurizio Marzegalli, Maurizio Lunati, Giovanni B Perego, Giuseppe Guenzati, Antonio Curnis, Sergio Valsecchi, Francesca Borghetti, Gabriella Borghi, Cristina Masella. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 30.05.2013. </copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p><!--CREATIVE COMMONS-->This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0/">http://creativecommons.org/licenses/by/2.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="http://www.jmir.org/,">http://www.jmir.org/,</ext-link> as well as this copyright and license information must be included.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="http://www.jmir.org/2013/5/e106/"/><abstract><sec sec-type="background"><title>Background</title><p>Heart failure patients with implantable defibrillators place a significant burden on health care systems. Remote monitoring allows assessment of device function and heart failure parameters, and may represent a safe, effective, and cost-saving method compared to conventional in-office follow-up.</p></sec><sec sec-type="objective"><title>Objective</title><p>We hypothesized that remote device monitoring represents a cost-effective approach. This paper summarizes the economic evaluation of the Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators (EVOLVO) study, a multicenter clinical trial aimed at measuring the benefits of remote monitoring for heart failure patients with implantable defibrillators.</p></sec><sec sec-type="methods"><title>Methods</title><p>Two hundred patients implanted with a wireless transmission&#x02013;enabled implantable defibrillator were randomized to receive either remote monitoring or the conventional method of in-person evaluations. Patients were followed for 16 months with a protocol of scheduled in-office and remote follow-ups. The economic evaluation of the intervention was conducted from the perspectives of the health care system and the patient. A cost-utility analysis was performed to measure whether the intervention was cost-effective in terms of cost per quality-adjusted life year (QALY) gained.</p></sec><sec sec-type="results"><title>Results</title><p>Overall, remote monitoring did not show significant annual cost savings for the health care system (&#x020ac;1962.78 versus &#x020ac;2130.01; <italic>P</italic>=.80). There was a significant reduction of the annual cost for the patients in the remote arm in comparison to the standard arm (&#x020ac;291.36 versus &#x020ac;381.34; <italic>P</italic>=.01). Cost-utility analysis was performed for 180 patients for whom QALYs were available. The patients in the remote arm gained 0.065 QALYs more than those in the standard arm over 16 months, with a cost savings of &#x020ac;888.10 per patient. Results from the cost-utility analysis of the EVOLVO study show that remote monitoring is a cost-effective and dominant solution.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Remote management of heart failure patients with implantable defibrillators appears to be cost-effective compared to the conventional method of in-person evaluations.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov NCT00873899; http://clinicaltrials.gov/show/NCT00873899 (Archived by WebCite at http://www.webcitation.org/6H0BOA29f).</p></sec></abstract><kwd-group><kwd>telemedicine</kwd><kwd>heart failure</kwd><kwd>implantable defibrillators</kwd><kwd>cost-effectiveness</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Recent guidelines based on the evidence from randomized controlled trials recommend the use of implantable cardioverter defibrillators (ICD) and defibrillators for cardiac resynchronization therapy (CRT-D) for the management of chronic heart failure (HF) patients [<xref ref-type="bibr" rid="ref1">1</xref>]. The conventional approach to cardiac device follow-up consists of scheduled in-office visits at intervals ranging from 3 to 6 months [<xref ref-type="bibr" rid="ref2">2</xref>]. Because of increasing patient volumes, routine follow-up contributes a significant burden to already overstrained clinics in terms of time, capital, and human resources required, and to patients and caregivers in terms of travel and time. Remote monitoring allows assessment of device function [<xref ref-type="bibr" rid="ref3">3</xref>] and patients&#x02019; HF-related parameters at home [<xref ref-type="bibr" rid="ref4">4</xref>], and may represent a safe, effective, and cost-saving way to significantly reduce in-office follow-up visits that are a burden for both hospitals and patients [<xref ref-type="bibr" rid="ref5">5</xref>].</p><p>Cost-effectiveness and cost-utility analyses are scientific approaches that can help justify the value of new interventions and, thus, informs both medical decision making and public policy [<xref ref-type="bibr" rid="ref6">6</xref>]. Remote monitoring programs for HF have shown a positive effect on clinical outcomes [<xref ref-type="bibr" rid="ref7">7</xref>]. However, the evidence for cost-effectiveness is limited and does not include the full range of perspectives [<xref ref-type="bibr" rid="ref8">8</xref>]. In 2002, a systematic review of cost-effectiveness studies of telemedicine interventions concluded that there was no good evidence that telemedicine is a cost-effective means of delivering health care, but none of the studies used cost-utility [<xref ref-type="bibr" rid="ref9">9</xref>]. In a recent systematic review of 47 economic evaluations of telemedicine interventions from 2004 to 2010, 11 were cost-effective analyses and 7 were cost-utility analyses [<xref ref-type="bibr" rid="ref10">10</xref>]. In a meta-analysis of 14 randomized clinical trials of remote monitoring for patients with HF, only 4 studies using structured telephone support examined health care costs [<xref ref-type="bibr" rid="ref11">11</xref>].</p><p>Thus, prospective health-economic studies are needed to correctly determine the clinical and economic benefits of systematic remote monitoring in patients with ICD and CRT-D [<xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref12">12</xref>]. We conducted a multicenter clinical trial, the Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators (EVOLVO) study (ClinicalTrials.gov NCT00873899), aimed at measuring the benefits of remote monitoring of chronic HF patients implanted with wireless transmission-enabled ICD/CRT-D endowed with specific diagnostic features for HF [<xref ref-type="bibr" rid="ref13">13</xref>]. The primary clinical endpoint of the EVOLVO study was to determine whether remote monitoring was associated with different rates of emergency department (ED) and urgent in-office visits for HF, arrhythmias, or ICD-related events compared to patients in the standard-treatment arm. Details of primary and secondary clinical endpoints are published elsewhere [<xref ref-type="bibr" rid="ref14">14</xref>]. This paper focuses on the economic evaluation of the intervention and its cost utility. We hypothesized that remote device monitoring represents a cost-effective approach.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study Design</title><p>The study design is described in detail elsewhere [<xref ref-type="bibr" rid="ref13">13</xref>]. Briefly, the EVOLVO study is a prospective, randomized, open, multicenter clinical trial designed to compare remote monitoring of chronic HF patients with ICD/CRT-D (remote arm) to the current standard of care (standard arm; ClinicalTrials.gov NCT00873899). Two hundred patients implanted with a Medtronic (Minneapolis, MN, USA) wireless transmission-enabled ICD/CRT-D were enrolled by 6 Italian hospitals and randomized to receive either the Medtronic CareLink Home Monitor for remote transmission [<xref ref-type="bibr" rid="ref15">15</xref>] (<xref ref-type="fig" rid="figure1">Figure 1</xref>) or the conventional method of in-person evaluations. Patients in the standard arm were followed for a 16-month period with scheduled in-office visits at 4, 8, 12, and 16 months. For the remote arm, patients had in-office visits at 8 and 16 months, but remote transmissions replaced their in-office visits at 4 and 12 months. In the remote arm, all alerts regarding clinical management (intrathoracic impedance for fluid accumulation monitoring, atrial arrhythmias, and ICD shocks delivered) were turned on for wireless notification through the CareLink Home Monitor, but no audible alerts were used. Hospital staff accessed patients&#x02019; data via the Web-based Medtronic CareLink Network (<xref ref-type="fig" rid="figure2">Figure 2</xref>). In the standard arm, patients did not have access to the CareLink Network, and the alerts were turned on for audible notification only. All system-integrity alerts were turned on for both wireless and audible notification in the remote arm and for only audible notification in the standard arm. Management strategies and data collection were predefined and have been previously described [<xref ref-type="bibr" rid="ref13">13</xref>].</p><p>The research protocol of this study was approved by the Institutional Review Boards of the 6 participating hospitals (4 hospitals in Milan, 1 in Pavia, and 1 in Brescia). The investigation conforms to the principles outlined in the Declaration of Helsinki. All patients gave written informed consent. This trial is reported in accordance with the Consolidated Standards of Reporting Trials of Electronic and Mobile Health Applications and Online Telehealth (CONSORT-EHEALTH) [<xref ref-type="bibr" rid="ref16">16</xref>].</p><fig id="figure1" position="float"><label>Figure 1</label><caption><p>Medtronic CareLink home monitor.</p></caption><graphic xlink:href="jmir_v15i5e106_fig1"/></fig><fig id="figure2" position="float"><label>Figure 2</label><caption><p>Medtronic Carelink Network.</p></caption><graphic xlink:href="jmir_v15i5e106_fig2"/></fig></sec><sec><title>Objectives</title><p>This paper summarizes the economic evaluation of the intervention. The analysis was conducted with the perspectives of the health care system and the patient. A cost-utility analysis was performed to measure whether the intervention was cost-effective in terms of cost per quality-adjusted life year (QALY) gained.</p></sec><sec><title>Health Care System Perspective</title><p>The objective of this analysis was to determine whether the total costs incurred by the health care authority for the patients in the remote arm were different from those in the standard arm. Costs included urgent and nonurgent in-office visits, scheduled and unscheduled remote follow-ups, ED visits, hospitalizations, and diagnostic examinations. All costs are expressed in Euro (&#x020ac;) and refer to the fiscal year 2010. A top-down approach was used for in-office visits, ED visits, hospitalizations, and diagnostic examinations. These costs, therefore, correspond to the specific public tariffs from the diagnosis-related group (DRG) system offered by the regional health care authority. Remote follow-ups were not covered by an official reimbursement scheme in Italy at the time this study was conducted, as in other European countries [<xref ref-type="bibr" rid="ref17">17</xref>]. However, the attribution of an economic value to remote follow-ups was necessary to properly include their cost for the health care system and to compare remote to standard management. In the countries where a reimbursement for remote follow-ups is recognized, this is in-line with that of in-office visits [<xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref>]. Thus, the cost of a remote follow-up was assumed to be equal to that of an in-office visit, and reduced by 50% if not followed with a phone call to the patient. In Italy and other countries, the use of the technology (the remote monitoring device, network server, and website) is included in the initial cost of the ICD without any adjunctive fee [<xref ref-type="bibr" rid="ref20">20</xref>], thus it does not represent a marginal cost in the economic evaluation.</p><p>However, the introduction of a yearly fee to device manufacturers covering the use of technology is a current topic of debate [<xref ref-type="bibr" rid="ref21">21</xref>]. France is the only European country where the service is covered by the national health care insurance, with an average fee of &#x020ac;900 for the life of the device [<xref ref-type="bibr" rid="ref22">22</xref>]. Therefore, a different scenario was included assuming a fee of &#x020ac;900 per patient for renting the remote monitoring device, the network server, and the website. An average device life span of 5 years was assumed according to recent studies [<xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref>]. In the EVOLVO study, the patients in both study arms were implanted with the same devices (ie, remote monitoring capabilities were available for both the intervention arm and the control arm). Therefore, the cost of the device was not included in the economic evaluation because it did not represent a marginal cost. All Medtronic ICDs currently sold in the Italian market have remote monitoring capabilities, as do most ICDs sold in Italy. Moreover, the tariff received by the hospitals for an ICD implantation is fixed and it does not vary according to the type of device implanted. New hardware investments were not requested for remote monitoring in the hospitals because the existent information technology services of the hospitals were sufficient to support the transmissions. Transportation costs were included in the patient perspective only because they are not reimbursed by the health care system. Data regarding the number of activities provided and events occurring to patients during the study period were systematically collected in an electronic database.</p></sec><sec><title>Patient Perspective</title><p>The objective of this analysis was to determine whether the costs for in-office and ED visits incurred by patients and their caregivers in the remote arm were different from those in the standard arm. The cost of each visit was related to out-of-pocket expenses, including transportation, room and board, and wages lost by patients and family caregivers. Because the newest generation of Medtronic devices are able to automatically transmit data wirelessly, the time used by patients for remote follow-ups was null. These data were collected through questionnaires administered to patients at baseline. Fares of &#x020ac;0.47 per kilometer and &#x020ac;25.67 per hour were used for travel by car and by taxi, respectively. Patient-reported costs were used for other means of transportation and room and board. National wage data were used to calculate wages lost by patients and family caregivers. Hourly wages of &#x020ac;7.82, &#x020ac;10.19, &#x020ac;18.99, &#x020ac;15.06, and &#x020ac;10.40 were used for workers, employees, managers, entrepreneurs, and other self-employed workers, respectively.</p></sec><sec><title>Cost-Utility Analysis</title><p>A cost-utility analysis was conducted using the costs assessed with the health care system perspective and QALYs. QALYs were calculated based on the answers of the EQ-5D questionnaires submitted by each patient at baseline and at 16 months. Utility values (from 0 to 1) were calculated using the European EQ-net VAS set [<xref ref-type="bibr" rid="ref25">25</xref>]. Utility values were calculated only if all 5 of the EQ-5D dimensions were answered. Moreover, missing utility values at the study exit were imputed using regression models [<xref ref-type="bibr" rid="ref26">26</xref>], in which the dependent variable was the utility value at 16 months, and the independent variable was the baseline value. Finally, the cost-utility ratio was computed as differential costs between remote arm and standard arm over 16 months, and differential QALYs. Because of the presence of a baseline imbalance in mean utility values between the study arms, a regression-based adjustment was applied to calculate differential QALYs controlling for baseline utility values [<xref ref-type="bibr" rid="ref27">27</xref>].</p></sec><sec><title>Statistical Analysis</title><p>Descriptive statistics were reported as mean and standard deviation (SD) for normally distributed continuous variables or median and interquartile range (IQR) in the case of skewed distributions. Normality of distribution of statistics was tested by means of the nonparametric Kolmogorov&#x02013;Smirnov test. Differences between mean data were compared by using <italic>t</italic> tests. A Mann&#x02013;Whitney nonparametric test was used to compare non-Gaussian variables. Differences in proportions were compared by using chi-square (&#x003c7;<sup>2</sup>) tests.</p><p>Cost data are typically highly skewed because a few patients incur particularly high costs. Despite the usual skewness in the distribution of costs, statistical analysis comparing medians and using standard nonparametric methods may provide misleading conclusions [<xref ref-type="bibr" rid="ref28">28</xref>]. The arithmetic mean is the most informative measure for policy decisions, and the <italic>t</italic> test on untransformed data is appropriate for costs because it is the only method addressing a comparison of arithmetic means [<xref ref-type="bibr" rid="ref29">29</xref>]. Moreover, the <italic>t</italic> test is considered reliable for moderately large sample sizes. Therefore, the <italic>t</italic> test was used for cost analyses. A <italic>P</italic> value &#x0003c;.05 was considered significant. All statistical analyses were performed by using IBM SPSS Statistics version 19 (IBM SPSS, New York, NY, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Baseline Characteristics and Summary of Clinical Endpoints</title><p>
<xref ref-type="table" rid="table1">Table 1</xref> summarizes the baseline characteristics of patients. Ninety-nine patients were randomly assigned to the remote arm and 101 patients to the standard arm. Demographic and clinical parameters were similar between the study arms. Fifteen patients died during the course of the study (7 in the remote arm and 8 in the standard arm), and 9 patients were withdrawn (3 patients in the remote arm and 6 in the standard arm) (<xref ref-type="fig" rid="figure3">Figure 3</xref>). <xref ref-type="table" rid="table2">Table 2</xref> summarizes the results of the primary and secondary clinical endpoints, expressed as number of events and annualized rates per patient-year. A detailed analysis of the baseline characteristics of patients and the clinical endpoints is published elsewhere [<xref ref-type="bibr" rid="ref14">14</xref>].</p></sec><sec><title>Health Care System Costs</title><p>The cost of in-office visits was &#x020ac;23.75, the mean cost of ED visits was &#x020ac;28.91 (range &#x020ac;22.38-&#x020ac;29.69), the mean cost of hospitalizations was &#x020ac;3865.45 (range &#x020ac;213.61-&#x020ac;25,727.70), and the mean cost of diagnostic examinations was &#x020ac;17.71 (range &#x020ac;3.95-&#x020ac;102.93). The mean annual cost for the management of the patients in the remote arm was lower than that in the standard arm (&#x020ac;1962.78 versus &#x020ac;2130.01; <italic>P</italic>=.80), although statistical significance was not reached (<xref ref-type="table" rid="table3">Table 3</xref>). Overall, remote monitoring of HF patients with implantable defibrillators did not show significant annual cost savings for the health care system. Focusing on the cost components, remote monitoring implied, on average, a lower cost for protocol-defined clinic visits than the standard management, since 2 of 4 in-office visits were replaced by scheduled remote follow-ups. According to the primary clinical endpoint, the cost of ED visits and urgent in-office visits was statistically significantly lower in the remote arm (<italic>P</italic>=.04). But remote monitoring required higher costs for nonurgent in-office visits, and an additional cost to perform unscheduled remote follow-ups as a consequence of automatic wireless remote notifications via CareLink. Most of the annual cost savings (&#x020ac;223.80) were from hospitalizations, which represents the main cost component (91% of the annual cost in the standard arm). Specifically, some of the patients in the standard arm experienced a higher number of HF-related hospitalizations compared to the patients in the remote arm. However, no statistically significant difference was detected between the 2 groups. Finally, the cost of diagnostic examinations was similar between the 2 groups.</p><table-wrap id="table1" position="float"><label>Table 1</label><caption><p>Demographics and baseline clinical characteristics of patients at the time of enrollment (N=200).</p></caption><table frame="hsides" rules="groups" width="583" border="1" cellpadding="4" cellspacing="0"><col width="39" span="1"/><col width="250" span="1"/><col width="94" span="1"/><col width="88" span="1"/><col width="70" span="1"/><thead><tr valign="top"><td colspan="2" rowspan="1">Patient characteristics</td><td rowspan="1" colspan="1">Standard arm (n=101)</td><td rowspan="1" colspan="1">Remote arm (n=99)</td><td rowspan="1" colspan="1">
<italic>P</italic> value</td></tr></thead><tbody><tr valign="top"><td colspan="2" rowspan="1">Male gender, n (%)</td><td rowspan="1" colspan="1">76 (75.2)</td><td rowspan="1" colspan="1">81 (81.9)</td><td rowspan="1" colspan="1">.34</td></tr><tr valign="top"><td colspan="2" rowspan="1">Age (years), median (IQR)</td><td rowspan="1" colspan="1">69 (60-73)</td><td rowspan="1" colspan="1">66 (60-72)</td><td rowspan="1" colspan="1">.14</td></tr><tr valign="top"><td colspan="2" rowspan="1">
<bold>New York Heart Association (NYHA) class, n (%)</bold>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">.80</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Class I</td><td rowspan="1" colspan="1">13 (12.9)</td><td rowspan="1" colspan="1">11 (11.1)</td><td rowspan="1" colspan="1">
<break/>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Class II</td><td rowspan="1" colspan="1">68 (67.3)</td><td rowspan="1" colspan="1">71 (71.7)</td><td rowspan="1" colspan="1">
<break/>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Class III</td><td rowspan="1" colspan="1">20 (19.8)</td><td rowspan="1" colspan="1">17 (17.2)</td><td rowspan="1" colspan="1">
<break/>
</td></tr><tr valign="top"><td colspan="2" rowspan="1">Primary prevention, n (%)</td><td rowspan="1" colspan="1">95 (94.1)</td><td rowspan="1" colspan="1">87 (87.9)</td><td rowspan="1" colspan="1">.20</td></tr><tr valign="top"><td colspan="2" rowspan="1">Time since implantation &#x0003e;6 months, n (%)</td><td rowspan="1" colspan="1">46 (45.5)</td><td rowspan="1" colspan="1">45 (45.5)</td><td rowspan="1" colspan="1">.90</td></tr><tr valign="top"><td colspan="2" rowspan="1">
<bold>Comorbidities, n (%)</bold>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">52 (51.5)</td><td rowspan="1" colspan="1">46 (46.5)</td><td rowspan="1" colspan="1">.57</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Diabetes</td><td rowspan="1" colspan="1">26 (25.7)</td><td rowspan="1" colspan="1">22 (22.2)</td><td rowspan="1" colspan="1">.68</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Chronic kidney disease</td><td rowspan="1" colspan="1">22 (21.8)</td><td rowspan="1" colspan="1">21 (21.2)</td><td rowspan="1" colspan="1">1.00</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">COPD</td><td rowspan="1" colspan="1">15 (14.9)</td><td rowspan="1" colspan="1">19 (19.2)</td><td rowspan="1" colspan="1">.50</td></tr><tr valign="top"><td colspan="2" rowspan="1">LV ejection fraction (%), median (IQR)</td><td rowspan="1" colspan="1">30 (25-34)</td><td rowspan="1" colspan="1">31 (25-35)</td><td rowspan="1" colspan="1">.39</td></tr></tbody></table></table-wrap><table-wrap id="table2" position="float"><label>Table 2</label><caption><p>Summary of the clinical endpoints expressed as number of events (annualized rate per patient-year).</p></caption><table frame="hsides" rules="groups" width="607" border="1" cellpadding="4" cellspacing="0"><col width="21" span="1"/><col width="202" span="1"/><col width="130" span="1"/><col width="148" span="1"/><col width="64" span="1"/><thead><tr valign="top"><td colspan="2" rowspan="1">Clinical endpoints</td><td colspan="2" rowspan="1">Events, n (annualized rate per patient-year)</td><td rowspan="1" colspan="1">
<italic>P</italic> value</td></tr><tr valign="top"><td colspan="2" rowspan="1">
<break/>
</td><td rowspan="1" colspan="1">Standard arm (n=101)</td><td rowspan="1" colspan="1">Remote arm (n=99)</td><td rowspan="1" colspan="1">
<break/>
</td></tr></thead><tbody><tr valign="top"><td colspan="2" rowspan="1">
<bold>Primary endpoint</bold>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">ED/urgent in-office visits for HF, arrhythmias, or ICD-related events</td><td rowspan="1" colspan="1">117 (0.93)</td><td rowspan="1" colspan="1">75 (0.59)</td><td rowspan="1" colspan="1">.005</td></tr><tr valign="top"><td colspan="2" rowspan="1">
<bold>Secondary endpoints</bold>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">ED/urgent in-office visits for HF</td><td rowspan="1" colspan="1">92 (0.73)</td><td rowspan="1" colspan="1">48 (0.38)</td><td rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">ED/urgent in-office visits for arrhythmias or ICD-related events</td><td rowspan="1" colspan="1">25 (0.20)</td><td rowspan="1" colspan="1">27 (0.21)</td><td rowspan="1" colspan="1">.65</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Total health care utilizations</td><td rowspan="1" colspan="1">726 (5.76)</td><td rowspan="1" colspan="1">559 (4.40)</td><td rowspan="1" colspan="1">&#x0003c;.001</td></tr></tbody></table></table-wrap><fig id="figure3" position="float"><label>Figure 3</label><caption><p>Consolidated Standards of Reporting Trials (CONSORT) diagram of the study.</p></caption><graphic xlink:href="jmir_v15i5e106_fig3"/></fig><table-wrap id="table3" position="float"><label>Table 3</label><caption><p>Comparison of health care system costs.</p></caption><table frame="hsides" rules="groups" width="651" border="1" cellpadding="2" cellspacing="0"><col width="193" span="1"/><col width="118" span="1"/><col width="109" span="1"/><col width="166" span="1"/><col width="43" span="1"/><thead><tr valign="top"><td rowspan="1" colspan="1">Health care system costs</td><td colspan="2" rowspan="1">Costs (&#x020ac;), mean (SD)</td><td rowspan="1" colspan="1">Mean difference (95% CI)</td><td rowspan="1" colspan="1">
<italic>P</italic> value</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Standard arm (n=101)</td><td rowspan="1" colspan="1">Remote arm (n=99)</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Protocol-defined clinic visits</td><td rowspan="1" colspan="1">90.29 (38.58)</td><td rowspan="1" colspan="1">56.63 (38.64)</td><td rowspan="1" colspan="1">33.66 (22.89, 44.43)</td><td rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr valign="top"><td rowspan="1" colspan="1">ED visits and urgent in-office visits</td><td rowspan="1" colspan="1">23.60 (33.68)</td><td rowspan="1" colspan="1">14.80 (24.71)</td><td rowspan="1" colspan="1">8.81 (0.56, 17.06)</td><td rowspan="1" colspan="1">.04</td></tr><tr valign="top"><td rowspan="1" colspan="1">Nonurgent in-office visits</td><td rowspan="1" colspan="1">20.13 (38.71)</td><td rowspan="1" colspan="1">30.81 (72.13)</td><td rowspan="1" colspan="1">&#x02013;10.68 (&#x02013;26.78, 5.42)</td><td rowspan="1" colspan="1">.19</td></tr><tr valign="top"><td rowspan="1" colspan="1">Scheduled remote follow-ups</td><td rowspan="1" colspan="1">0.00 (0.00)</td><td rowspan="1" colspan="1">32.50 (9.20)</td><td rowspan="1" colspan="1">&#x02013;32.50 (&#x02013;34.34, &#x02013;30.67)</td><td rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr valign="top"><td rowspan="1" colspan="1">Unscheduled remote follow-ups</td><td rowspan="1" colspan="1">0.00 (0.00)</td><td rowspan="1" colspan="1">56.42 (58.95)</td><td rowspan="1" colspan="1">&#x02013;56.42 (&#x02013;68.18, 44.67)</td><td rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr valign="top"><td rowspan="1" colspan="1">Hospitalizations</td><td rowspan="1" colspan="1">1945.82 (5247.62)</td><td rowspan="1" colspan="1">1722.02 (4106.00)</td><td rowspan="1" colspan="1">223.80 (&#x02013;1091.83, 1539.44)</td><td rowspan="1" colspan="1">.74</td></tr><tr valign="top"><td rowspan="1" colspan="1">Diagnostic examinations</td><td rowspan="1" colspan="1">50.16 (73.23)</td><td rowspan="1" colspan="1">49.60 (77.80)</td><td rowspan="1" colspan="1">0.56 (&#x02013;20.50, 21.63)</td><td rowspan="1" colspan="1">.96</td></tr><tr valign="top"><td rowspan="1" colspan="1">Mean annual cost per patient</td><td rowspan="1" colspan="1">2130.01 (5251.33)</td><td rowspan="1" colspan="1">1962.78 (4185.61)</td><td rowspan="1" colspan="1">167.23 (&#x02013;1158.61, 1493.06)</td><td rowspan="1" colspan="1">.80</td></tr></tbody></table></table-wrap></sec><sec><title>Patient Costs</title><p>The mean cost of in-hospital visits was &#x020ac;68.37 (range &#x020ac;0-&#x020ac;1720). Results summarized in <xref ref-type="table" rid="table4">Table 4</xref> show a statistically significant reduction of the annual cost for the patients in the remote arm in comparison to that in the standard arm (&#x020ac;291.36 versus &#x020ac;381.34; <italic>P</italic>=.01). Remote monitoring of HF patients with implantable defibrillators, therefore, implied cost savings to patients of 24% of their total annual cost. In particular, cost savings are because of a reduction in the number of protocol-defined clinic visits, replaced by remote follow-ups for the patients in the remote arm, together with a reduction of ED visits and urgent in-office visits.</p></sec><sec><title>Cost-Utility</title><p>The EQ-5D scores at baseline and 16 months were complete for 144 patients. Fifteen patients died during the study period; therefore, a 0 utility value was assigned at the study exit. By using imputed utility missing values for 21 patients with incomplete data at 16 months, QALYs were available for 180 patients, 91 in the standard arm and 89 in the remote arm. Cost data were available for all those patients. Results from the cost-utility analysis are summarized in <xref ref-type="table" rid="table5">Table 5</xref>.</p><p>Mean utility values at baseline were slightly imbalanced between the remote arm and standard arm, but not significantly different (0.793 versus 0.737; <italic>P</italic>=.08). Controlling for baseline, there was a differential QALY of 0.065 between the study arms (1.032 versus 0.966; <italic>P</italic>=.03). The mean cost for the patients in the remote arm was lower than that in the standard arm (&#x020ac;2074.70 versus &#x020ac;2962.80; <italic>P</italic>=.33), although statistical significance was not reached. Therefore, patients in the remote arm gained 0.065 QALYs more than those in the standard arm, with a cost savings of &#x020ac;888.10 per patient over the 16-month study period. The cost-utility ratio was negative. As a consequence, the cost-utility analysis showed that remote monitoring is cost-effective compared to the conventional follow-up, representing a dominant solution. Assuming a fee of &#x020ac;900 per patient for using the technology over 5 years, the mean cost for the patients in the remote arm was still lower than that in the standard arm (&#x020ac;2304.95 versus &#x020ac;2962.80), with a negative cost-utility ratio.</p><table-wrap id="table4" position="float"><label>Table 4</label><caption><p>Comparison of patient costs.</p></caption><table frame="hsides" rules="groups" width="645" border="1" cellpadding="4" cellspacing="0"><col width="180" span="1"/><col width="115" span="1"/><col width="105" span="1"/><col width="153" span="1"/><col width="50" span="1"/><thead><tr valign="top"><td rowspan="1" colspan="1">Patient costs</td><td colspan="2" rowspan="1">Costs (&#x020ac;), mean (SD)</td><td rowspan="1" colspan="1">Mean difference (95% CI)</td><td rowspan="1" colspan="1">
<italic>P</italic> value</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Standard arm (n=101)</td><td rowspan="1" colspan="1">Remote arm (n=99)</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Protocol-defined clinic visits</td><td rowspan="1" colspan="1">259.91 (111.07)</td><td rowspan="1" colspan="1">163.01 (111.23)</td><td rowspan="1" colspan="1">96.90 (65.90, 127.90)</td><td rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr valign="top"><td rowspan="1" colspan="1">ED visits and urgent in-office visits</td><td rowspan="1" colspan="1">63.48 (87.29)</td><td rowspan="1" colspan="1">39.68 (66.31)</td><td rowspan="1" colspan="1">23.81 (2.16, 45.45)</td><td rowspan="1" colspan="1">.03</td></tr><tr valign="top"><td rowspan="1" colspan="1">Nonurgent in-office visits</td><td rowspan="1" colspan="1">57.93 (111.44)</td><td rowspan="1" colspan="1">88.67 (207.63)</td><td rowspan="1" colspan="1">&#x02013;30.74 (&#x02013;77.08, 15.60)</td><td rowspan="1" colspan="1">.19</td></tr><tr valign="top"><td rowspan="1" colspan="1">Mean annual cost per patient</td><td rowspan="1" colspan="1">381.34 (202.98)</td><td rowspan="1" colspan="1">291.36 (305.53)</td><td rowspan="1" colspan="1">89.97 (17.78, 162.17)</td><td rowspan="1" colspan="1">.01</td></tr></tbody></table></table-wrap><table-wrap id="table5" position="float"><label>Table 5</label><caption><p>Utility values, quality-adjusted life years (QALYs), and cost per patient over the 16-month study period.</p></caption><table frame="hsides" rules="groups" width="645" border="1" cellpadding="4" cellspacing="0"><col width="171" span="1"/><col width="110" span="1"/><col width="110" span="1"/><col width="153" span="1"/><col width="59" span="1"/><thead><tr valign="top"><td rowspan="1" colspan="1">Cost-utility variables</td><td colspan="2" rowspan="1">Value, mean (SD)</td><td rowspan="1" colspan="1">Mean difference (95% CI)</td><td rowspan="1" colspan="1">
<italic>P</italic> value</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Standard arm (n=91)</td><td rowspan="1" colspan="1">Remote arm (n=89)</td><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">
<break/>
</td></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Mean utility value at baseline</td><td rowspan="1" colspan="1">0.737 (0.234)</td><td rowspan="1" colspan="1">0.793 (0.179)</td><td rowspan="1" colspan="1">&#x02013;0.055 (&#x02013;0.117, 0.006)</td><td rowspan="1" colspan="1">.08</td></tr><tr valign="top"><td rowspan="1" colspan="1">Mean utility value at 16 months</td><td rowspan="1" colspan="1">0.711 (0.305)</td><td rowspan="1" colspan="1">0.754 (0.275)</td><td rowspan="1" colspan="1">&#x02013;0.043 (&#x02013;0.128, 0.043)</td><td rowspan="1" colspan="1">.32</td></tr><tr valign="top"><td rowspan="1" colspan="1">QALYs (controlling for baseline)</td><td rowspan="1" colspan="1">0.966 (0.231)</td><td rowspan="1" colspan="1">1.032 (0.177)</td><td rowspan="1" colspan="1">&#x02013;0.066 (&#x02013;0.126, &#x02013;0.005)</td><td rowspan="1" colspan="1">.03</td></tr><tr valign="top"><td rowspan="1" colspan="1">Mean cost per patient (&#x020ac;)</td><td rowspan="1" colspan="1">2962.80 (7323.93)</td><td rowspan="1" colspan="1">2074.70 (4581.30)</td><td rowspan="1" colspan="1">&#x02013;888.10 (&#x02013;906.75, 2682.95)</td><td rowspan="1" colspan="1">.33</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Principal Findings</title><p>The results from the cost-utility analysis of the EVOLVO study show that chronic HF patients wearing ICD/CRT-D followed with remote monitoring gained 0.065 QALYs more than those in the standard arm over the 16-month study period, with a cost savings of &#x020ac;888.10 per patient. Remote monitoring, therefore, appears to be a cost-effective and dominant solution compared to conventional in-office follow-up. The cost-effectiveness ratio remains negative even including a fee for the use of technology in the analysis, currently adopted only in France. These results are in-line with a meta-analysis in which cost savings from remote monitoring in HF in comparison to usual care ranged from &#x020ac;300 to &#x020ac;1000, with a QALY gain of 0.06 [<xref ref-type="bibr" rid="ref30">30</xref>]. Results from cost-utility analyses have clear implications to inform policy makers and payers. Cost per QALY of new health interventions are often grouped in league tables, in which interventions at the top should take priority. Decisions regarding implementation can then be based on threshold values for the cost per QALY, which represents the willingness of society to pay for additional QALYs. For instance, the National Institute for Clinical Excellence (NICE) has set a range of acceptable cost-effectiveness from &#x000a3;20,000 to &#x000a3;30,000 per QALY [<xref ref-type="bibr" rid="ref31">31</xref>], and a US $50,000 per QALY threshold has been widely used in the United States for renal dialysis [<xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref32">32</xref>]. Remote monitoring of HF patients with implantable defibrillators could be taken into consideration for large-scale implementation.</p><p>Mean costs for the health care system provide another informative measure for policy decisions and confirm that the remote device monitoring might become an institutionalized service [<xref ref-type="bibr" rid="ref33">33</xref>]. Our analysis showed that the mean annual cost for the management of the patients in the remote arm was &#x020ac;167.23 lower than that in the standard arm (&#x020ac;1962.78 versus &#x020ac;2130.01; <italic>P</italic>=.80). The cost of scheduled and unscheduled remote follow-ups, assuming a hypothetical tariff in-line with that of in-office visits, accounted for &#x020ac;68.92. Therefore, according to the specific results from the EVOLVO study, the maximum value that could be allocated by the health care authority to remote monitoring of HF patients implanted with ICD/CRT-D without increasing the total budget is &#x020ac;256.15 per patient per year. In the Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) trial, the estimated mean cost per hospitalization was significantly lower because of the shorter hospital length of stay for the remote arm. However, more detailed cost data were not collected [<xref ref-type="bibr" rid="ref34">34</xref>]. The EVOLVO study confirms that remote monitoring implies major cost savings for hospitalizations, ED visits, and urgent in-office visits, which balance the additional cost to perform unscheduled remote follow-ups as a consequence of automatic wireless remote notifications. Moreover, as compared with standard management, remote monitoring increases the rate of appropriate in-hospital visits for clinically relevant device alerts, allows early detection of worsening symptoms [<xref ref-type="bibr" rid="ref35">35</xref>], and decreases the time from the alert condition to the data review [<xref ref-type="bibr" rid="ref14">14</xref>].</p><p>Implications for patients are positive and confirm the findings from previous studies. Remote monitoring has been demonstrated to be highly accepted and time saving for patients with ICD [<xref ref-type="bibr" rid="ref20">20</xref>]. Transportation costs are a major component of the overall costs of follow-up, and the potential savings have been previously estimated [<xref ref-type="bibr" rid="ref36">36</xref>]. The EVOLVO study provides new evidence of the economic benefits for patients and caregivers. The automatic data transmission eliminates the cost normally incurred to attend in-office visits. In our clinical protocol, 2 of 4 in-office visits were replaced by remote transmissions, with consequent savings. Additional benefits would clearly emerge if a higher number of in-office visits were replaced by remote follow-ups.</p></sec><sec><title>Limitations</title><p>We acknowledge 2 methodological limitations in the economic evaluation of the EVOLVO study. First, to include the cost of remote device monitoring in the absence of a reimbursement scheme, we assumed the cost of a remote follow-up based on the tariff of an in-office visit. In a European survey, 82% of the hospitals had no established reimbursement mechanism for remote follow-up. For cases in which reimbursement was present, this was established as a tariff per visit, an annual fee per patient, or charged as a service by private companies [<xref ref-type="bibr" rid="ref20">20</xref>]. In a Finnish study, the cost of a routine follow-up, including clinical and device evaluation by a cardiologist, was &#x020ac;210, whereas the fee per transmission evaluation was &#x020ac;55 [<xref ref-type="bibr" rid="ref19">19</xref>]. In a US study, the cost of device interrogation in-office and by remote monitoring were US $86.92 and US $102.79, respectively [<xref ref-type="bibr" rid="ref18">18</xref>]. The introduction of a reimbursement mechanism for remote ICD follow-up is currently under discussion in different Italian regions. The second limitation concerns the study design and the different management strategies for alerts in the 2 arms. The cost of protocol-defined clinic visits was lower in the intervention arm because, in this group, patients had remote transmissions replacing their in-office visits at 4 and 12 months, which are more costly than remote follow-ups. Moreover, the protocol imposed, for the standard arm, urgent visits for audible alerts.</p></sec><sec><title>Conclusions</title><p>The results from the cost-utility analysis of the EVOLVO study demonstrate that remote management of chronic HF patients with implantable defibrillators appears to be a cost-effective solution compared to the conventional method of in-person evaluations. Remote monitoring also implies significant cost savings for the patients. Today, an increasing number of outpatient clinics are already implementing remote monitoring in daily practice [<xref ref-type="bibr" rid="ref4">4</xref>]. Thus, a large-scale adoption could be supported.</p><p>The EVOLVO study summarizes the benefits of remote monitoring for a subgroup of the HF population, namely those patients with an implantable defibrillator. This is in-line with a recent Cochrane systematic literature review [<xref ref-type="bibr" rid="ref7">7</xref>], in which implications for research include the need for cost-effectiveness and the stratification of the benefits across the HF patient population. Future research should focus on intervention intensity and economic evaluations of large-scale studies to tailor remote monitoring for HF patients with implantable defibrillators to the population&#x02019;s needs and resources, to the geography of the population, and to patient preferences [<xref ref-type="bibr" rid="ref7">7</xref>].</p></sec></sec></body><back><ack><p>We are grateful to all investigators (physicians, nurses, and administrative staff) who have enthusiastically worked in the EVOLVO study. We also thank S Rusconi for his support in the analyses. The EVOLVO study was supported by the Italian Ministry of Health (grant RFPS-2006-2-335243) and by Regione Lombardia. Medtronic Italia provided technical support.</p></ack><fn-group><fn fn-type="conflict"><p>Conflicts of Interest: Dr Landolina has speakers&#x02019; bureau appointments and an advisory board relationship with Medtronic and other device companies. Valsecchi and Borghetti are employees of Medtronic Inc. The other authors report no conflicts.</p></fn></fn-group><app-group><app id="app1"><title>Multimedia Appendix 1</title><p>CONSORT-EHEALTH checklist V1.6.2 [<xref ref-type="bibr" rid="ref16">16</xref>].</p><fig id="d35e1374" position="anchor"><media xlink:href="jmir_v15i5e106_app1.pdf" mimetype="application" mime-subtype="pdf"/></fig></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">CONSORT</term><def><p>Consolidated Standards of Reporting Trials</p></def></def-item><def-item><term id="abb2">CRT-D</term><def><p>cardiac resynchronization therapy defibrillators</p></def></def-item><def-item><term id="abb3">DRG</term><def><p>diagnosis-related group</p></def></def-item><def-item><term id="abb4">ED</term><def><p>emergency department</p></def></def-item><def-item><term id="abb5">EVOLVO</term><def><p>Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators</p></def></def-item><def-item><term id="abb6">HF</term><def><p>heart failure</p></def></def-item><def-item><term id="abb7">ICD</term><def><p>implantable cardioverter defibrillators</p></def></def-item><def-item><term id="abb8">NICE</term><def><p>National Institute for Clinical Excellence</p></def></def-item><def-item><term id="abb9">NYHA</term><def><p>New York Heart Association</p></def></def-item><def-item><term id="abb10">QALY</term><def><p>quality-adjusted life year</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Vardas</surname><given-names>PE</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>McMurray</surname><given-names>J</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Sutton</surname><given-names>R</given-names></name><name><surname>van Veldhuisen</surname><given-names>DJ</given-names></name><collab>ESC Committee for Practice Guidelines (CPG)</collab></person-group><article-title>2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association</article-title><source>Eur Heart J</source><year>2010</year><month>11</month><volume>31</volume><issue>21</issue><fpage>2677</fpage><lpage>87</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/cgi/pmidlookup?view=long&#x00026;pmid=20801924"/></comment><pub-id pub-id-type="doi">10.1093/eurheartj/ehq337</pub-id><pub-id pub-id-type="medline">20801924</pub-id><!--<pub-id pub-id-type="pii">ehq337</pub-id>--><pub-id pub-id-type="pmid">20801924</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkoff</surname><given-names>BL</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Brugada</surname><given-names>J</given-names></name><name><surname>Cowie</surname><given-names>M</given-names></name><name><surname>Ellenbogen</surname><given-names>KA</given-names></name><name><surname>Gillis</surname><given-names>AM</given-names></name><name><surname>Hayes</surname><given-names>DL</given-names></name><name><surname>Howlett</surname><given-names>JG</given-names></name><name><surname>Kautzner</surname><given-names>J</given-names></name><name><surname>Love</surname><given-names>CJ</given-names></name><name><surname>Morgan</surname><given-names>JM</given-names></name><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Reynolds</surname><given-names>DW</given-names></name><name><surname>Schoenfeld</surname><given-names>MH</given-names></name><name><surname>Vardas</surname><given-names>PE</given-names></name><collab>Heart Rhythm Society (HRS)</collab><collab>European Heart Rhythm Association (EHRA)</collab><collab>American College of Cardiology (ACC)</collab><collab>American Heart Association (AHA)</collab><collab>European Society of Cardiology (ESC)</collab><collab>Heart Failure Association of ESC (HFA)</collab><collab>Heart Failure Society of America (HFSA)</collab></person-group><article-title>HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Failure Society of America (HFSA). Endorsed by the Heart Rhythm Society, the European Heart Rhythm Association (a registered branch of the ESC), the American College of Cardiology, the American Heart Association</article-title><source>Europace</source><year>2008</year><month>6</month><volume>10</volume><issue>6</issue><fpage>707</fpage><lpage>25</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x00026;pmid=18480075"/></comment><pub-id pub-id-type="doi">10.1093/europace/eun122</pub-id><pub-id pub-id-type="medline">18480075</pub-id><!--<pub-id pub-id-type="pii">eun122</pub-id>--><pub-id pub-id-type="pmid">18480075</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maass</surname><given-names>AH</given-names></name><name><surname>van Veldhuisen</surname><given-names>DJ</given-names></name></person-group><article-title>Remote monitoring via implanted devices in heart failure: rising star or lame duck?</article-title><source>Eur J Heart Fail</source><year>2011</year><month>9</month><volume>13</volume><issue>9</issue><fpage>925</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hfr096</pub-id><pub-id pub-id-type="medline">21852310</pub-id><!--<pub-id pub-id-type="pii">hfr096</pub-id>--><pub-id pub-id-type="pmid">21852310</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>AE</given-names></name><name><surname>van der Wal</surname><given-names>MH</given-names></name><name><surname>Nieuwenhuis</surname><given-names>MM</given-names></name><name><surname>de Jong</surname><given-names>RM</given-names></name><name><surname>van Dijk</surname><given-names>RB</given-names></name><name><surname>Jaarsma</surname><given-names>T</given-names></name><name><surname>Hillege</surname><given-names>HL</given-names></name></person-group><article-title>Health professionals' expectations versus experiences of internet-based telemonitoring: survey among heart failure clinics</article-title><source>J Med Internet Res</source><year>2013</year><volume>15</volume><issue>1</issue><fpage>e4</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.jmir.org/2013/1/e4/"/></comment><pub-id pub-id-type="doi">10.2196/jmir.2161</pub-id><pub-id pub-id-type="medline">23305645</pub-id><!--<pub-id pub-id-type="pii">v15i1e4</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC3636294</pub-id>--><pub-id pub-id-type="pmid">23305645</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidb&#x000fc;chel</surname><given-names>H</given-names></name><name><surname>Lioen</surname><given-names>P</given-names></name><name><surname>Foulon</surname><given-names>S</given-names></name><name><surname>Huybrechts</surname><given-names>W</given-names></name><name><surname>Ector</surname><given-names>J</given-names></name><name><surname>Willems</surname><given-names>R</given-names></name><name><surname>Ector</surname><given-names>H</given-names></name></person-group><article-title>Potential role of remote monitoring for scheduled and unscheduled evaluations of patients with an implantable defibrillator</article-title><source>Europace</source><year>2008</year><month>3</month><volume>10</volume><issue>3</issue><fpage>351</fpage><lpage>7</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x00026;pmid=18245771"/></comment><pub-id pub-id-type="doi">10.1093/europace/eun010</pub-id><pub-id pub-id-type="medline">18245771</pub-id><!--<pub-id pub-id-type="pii">eun010</pub-id>--><pub-id pub-id-type="pmid">18245771</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Winkelmayer</surname><given-names>WC</given-names></name><name><surname>Cohen</surname><given-names>DJ</given-names></name><name><surname>Berger</surname><given-names>ML</given-names></name><name><surname>Neumann</surname><given-names>PJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Weintraub</surname><given-names>WS</given-names></name></person-group><article-title>Comparing cost-utility analyses in cardiovascular medicine</article-title><source>Cardiovascular Health Care Economics</source><year>2003</year><publisher-loc>Totowa, NJ</publisher-loc><publisher-name>Humana Press</publisher-name><fpage>329</fpage><lpage>356</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inglis</surname><given-names>SC</given-names></name><name><surname>Clark</surname><given-names>RA</given-names></name><name><surname>McAlister</surname><given-names>FA</given-names></name><name><surname>Ball</surname><given-names>J</given-names></name><name><surname>Lewinter</surname><given-names>C</given-names></name><name><surname>Cullington</surname><given-names>D</given-names></name><name><surname>Stewart</surname><given-names>S</given-names></name><name><surname>Cleland</surname><given-names>JG</given-names></name></person-group><article-title>Structured telephone support or telemonitoring programmes for patients with chronic heart failure</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><issue>8</issue><fpage>CD007228</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD007228.pub2</pub-id><pub-id pub-id-type="medline">20687083</pub-id><pub-id pub-id-type="pmid">20687083</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname><given-names>S</given-names></name><name><surname>Protti</surname><given-names>D</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name></person-group><article-title>Telehealthcare for long term conditions</article-title><source>BMJ</source><year>2011</year><volume>342</volume><fpage>d120</fpage><pub-id pub-id-type="medline">21292710</pub-id><pub-id pub-id-type="pmid">21292710</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitten</surname><given-names>PS</given-names></name><name><surname>Mair</surname><given-names>FS</given-names></name><name><surname>Haycox</surname><given-names>A</given-names></name><name><surname>May</surname><given-names>CR</given-names></name><name><surname>Williams</surname><given-names>TL</given-names></name><name><surname>Hellmich</surname><given-names>S</given-names></name></person-group><article-title>Systematic review of cost effectiveness studies of telemedicine interventions</article-title><source>BMJ</source><year>2002</year><month>6</month><day>15</day><volume>324</volume><issue>7351</issue><fpage>1434</fpage><lpage>7</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/12065269"/></comment><pub-id pub-id-type="medline">12065269</pub-id><!--<pub-id pub-id-type="pmcid">PMC115857</pub-id>--><pub-id pub-id-type="pmid">12065269</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>H</given-names></name></person-group><article-title>Systematic review of studies of the cost-effectiveness of telemedicine and telecare. Changes in the economic evidence over twenty years</article-title><source>J Telemed Telecare</source><year>2012</year><month>1</month><volume>18</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1258/jtt.2011.110505</pub-id><pub-id pub-id-type="medline">22101609</pub-id><!--<pub-id pub-id-type="pii">jtt.2011.110505</pub-id>--><pub-id pub-id-type="pmid">22101609</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>RA</given-names></name><name><surname>Inglis</surname><given-names>SC</given-names></name><name><surname>McAlister</surname><given-names>FA</given-names></name><name><surname>Cleland</surname><given-names>JG</given-names></name><name><surname>Stewart</surname><given-names>S</given-names></name></person-group><article-title>Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis</article-title><source>BMJ</source><year>2007</year><month>5</month><day>5</day><volume>334</volume><issue>7600</issue><fpage>942</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.bmj.com/cgi/pmidlookup?view=long&#x00026;pmid=17426062"/></comment><pub-id pub-id-type="doi">10.1136/bmj.39156.536968.55</pub-id><pub-id pub-id-type="medline">17426062</pub-id><!--<pub-id pub-id-type="pii">bmj.39156.536968.55</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC1865411</pub-id>--><pub-id pub-id-type="pmid">17426062</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Veldhuisen</surname><given-names>DJ</given-names></name><name><surname>Maass</surname><given-names>AH</given-names></name></person-group><article-title>Telemonitoring of outpatients with heart failure: a search for the holy grail?</article-title><source>Circulation</source><year>2012</year><month>6</month><day>19</day><volume>125</volume><issue>24</issue><fpage>2965</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.118141</pub-id><pub-id pub-id-type="medline">22626742</pub-id><!--<pub-id pub-id-type="pii">CIRCULATIONAHA.112.118141</pub-id>--><pub-id pub-id-type="pmid">22626742</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzegalli</surname><given-names>M</given-names></name><name><surname>Landolina</surname><given-names>M</given-names></name><name><surname>Lunati</surname><given-names>M</given-names></name><name><surname>Perego</surname><given-names>GB</given-names></name><name><surname>Pappone</surname><given-names>A</given-names></name><name><surname>Guenzati</surname><given-names>G</given-names></name><name><surname>Campana</surname><given-names>C</given-names></name><name><surname>Frigerio</surname><given-names>M</given-names></name><name><surname>Parati</surname><given-names>G</given-names></name><name><surname>Curnis</surname><given-names>A</given-names></name><name><surname>Colangelo</surname><given-names>I</given-names></name><name><surname>Valsecchi</surname><given-names>S</given-names></name></person-group><article-title>Design of the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study to assess the ability of remote monitoring to treat and triage patients more effectively</article-title><source>Trials</source><year>2009</year><volume>10</volume><fpage>42</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.trialsjournal.com/content/10//42"/></comment><pub-id pub-id-type="doi">10.1186/1745-6215-10-42</pub-id><pub-id pub-id-type="medline">19538734</pub-id><!--<pub-id pub-id-type="pii">1745-6215-10-42</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC2705368</pub-id>--><pub-id pub-id-type="pmid">19538734</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landolina</surname><given-names>M</given-names></name><name><surname>Perego</surname><given-names>GB</given-names></name><name><surname>Lunati</surname><given-names>M</given-names></name><name><surname>Curnis</surname><given-names>A</given-names></name><name><surname>Guenzati</surname><given-names>G</given-names></name><name><surname>Vicentini</surname><given-names>A</given-names></name><name><surname>Parati</surname><given-names>G</given-names></name><name><surname>Borghi</surname><given-names>G</given-names></name><name><surname>Zanaboni</surname><given-names>P</given-names></name><name><surname>Valsecchi</surname><given-names>S</given-names></name><name><surname>Marzegalli</surname><given-names>M</given-names></name></person-group><article-title>Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study</article-title><source>Circulation</source><year>2012</year><month>6</month><day>19</day><volume>125</volume><issue>24</issue><fpage>2985</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.088971</pub-id><pub-id pub-id-type="medline">22626743</pub-id><!--<pub-id pub-id-type="pii">CIRCULATIONAHA.111.088971</pub-id>--><pub-id pub-id-type="pmid">22626743</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burri</surname><given-names>H</given-names></name><name><surname>Senouf</surname><given-names>D</given-names></name></person-group><article-title>Remote monitoring and follow-up of pacemakers and implantable cardioverter defibrillators</article-title><source>Europace</source><year>2009</year><month>6</month><volume>11</volume><issue>6</issue><fpage>701</fpage><lpage>9</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x00026;pmid=19470595"/></comment><pub-id pub-id-type="doi">10.1093/europace/eup110</pub-id><pub-id pub-id-type="medline">19470595</pub-id><!--<pub-id pub-id-type="pii">eup110</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC2686319</pub-id>--><pub-id pub-id-type="pmid">19470595</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eysenbach</surname><given-names>G</given-names></name><collab>CONSORT-EHEALTH Group</collab></person-group><article-title>CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions</article-title><source>J Med Internet Res</source><year>2011</year><volume>13</volume><issue>4</issue><fpage>e126</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.jmir.org/2011/4/e126/"/></comment><pub-id pub-id-type="doi">10.2196/jmir.1923</pub-id><pub-id pub-id-type="medline">22209829</pub-id><!--<pub-id pub-id-type="pii">v13i4e126</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC3278112</pub-id>--><pub-id pub-id-type="pmid">22209829</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sticherling</surname><given-names>C</given-names></name><name><surname>K&#x000fc;hne</surname><given-names>M</given-names></name><name><surname>Schaer</surname><given-names>B</given-names></name><name><surname>Altmann</surname><given-names>D</given-names></name><name><surname>Osswald</surname><given-names>S</given-names></name></person-group><article-title>Remote monitoring of cardiovascular implantable electronic devices: prerequisite or luxury?</article-title><source>Swiss Med Wkly</source><year>2009</year><month>10</month><day>17</day><volume>139</volume><issue>41-42</issue><fpage>596</fpage><lpage>601</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.smw.ch/dfe/set_archiv.asp?target=smw-12667"/></comment><pub-id pub-id-type="medline">19918698</pub-id><!--<pub-id pub-id-type="pii">smw-12667</pub-id>--><pub-id pub-id-type="pmid">19918698</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Khatib</surname><given-names>SM</given-names></name><name><surname>Piccini</surname><given-names>JP</given-names></name><name><surname>Knight</surname><given-names>D</given-names></name><name><surname>Stewart</surname><given-names>M</given-names></name><name><surname>Clapp-Channing</surname><given-names>N</given-names></name><name><surname>Sanders</surname><given-names>GD</given-names></name></person-group><article-title>Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial</article-title><source>J Cardiovasc Electrophysiol</source><year>2010</year><month>5</month><volume>21</volume><issue>5</issue><fpage>545</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8167.2009.01659.x</pub-id><pub-id pub-id-type="medline">20021522</pub-id><!--<pub-id pub-id-type="pii">JCE1659</pub-id>--><pub-id pub-id-type="pmid">20021522</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raatikainen</surname><given-names>MJ</given-names></name><name><surname>Uusimaa</surname><given-names>P</given-names></name><name><surname>van Ginneken</surname><given-names>MM</given-names></name><name><surname>Janssen</surname><given-names>JP</given-names></name><name><surname>Linnaluoto</surname><given-names>M</given-names></name></person-group><article-title>Remote monitoring of implantable cardioverter defibrillator patients: a safe, time-saving, and cost-effective means for follow-up</article-title><source>Europace</source><year>2008</year><month>10</month><volume>10</volume><issue>10</issue><fpage>1145</fpage><lpage>51</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x00026;pmid=18703585"/></comment><pub-id pub-id-type="doi">10.1093/europace/eun203</pub-id><pub-id pub-id-type="medline">18703585</pub-id><!--<pub-id pub-id-type="pii">eun203</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC2552405</pub-id>--><pub-id pub-id-type="pmid">18703585</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halimi</surname><given-names>F</given-names></name><name><surname>Cant&#x000f9;</surname><given-names>F</given-names></name><collab>European Heart Rhythm Association (EHRA) Scientific Initiatives Committee (SIC)</collab></person-group><article-title>Remote monitoring for active cardiovascular implantable electronic devices: a European survey</article-title><source>Europace</source><year>2010</year><month>12</month><volume>12</volume><issue>12</issue><fpage>1778</fpage><lpage>80</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x00026;pmid=21097482"/></comment><pub-id pub-id-type="doi">10.1093/europace/euq399</pub-id><pub-id pub-id-type="medline">21097482</pub-id><!--<pub-id pub-id-type="pii">euq399</pub-id>--><pub-id pub-id-type="pmid">21097482</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="book"><source>Moving towards good practice in reimbursement of CIED telemonitoring</source><year>2012</year><date-in-citation>2013-04-08</date-in-citation><publisher-loc>Germany</publisher-loc><publisher-name>PricewaterhouseCoopers</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://www.eucomed.org/uploads/Modules/Publications/whitepaper_reimbursementciedtelemonitoring.pdf">http://www.eucomed.org/uploads/Modules/Publications/whitepaper_reimbursementciedtelemonitoring.pdf</ext-link></comment><ext-link ext-link-type="webcite" xlink:href="6Fj5doQQa"/></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Minist&#x000e8;re du Travail de l&#x02019;Emploi et de la Sant&#x000e9;</collab></person-group><source>Journal Officiel De La R&#x000e9;publique Francaise</source><year>2012</year><month>1</month><day>24</day><comment>Avis et communications<ext-link ext-link-type="uri" xlink:href="http://www.legifrance.gouv.fr/jopdf/common/jo_pdf.jsp?numJO=0&#x00026;dateJO=20120124&#x00026;numTexte=137&#x00026;pageDebut=01355&#x00026;pageFin=01355">http://www.legifrance.gouv.fr/jopdf/common/jo_pdf.jsp?numJO=0&#x00026;dateJO=20120124&#x00026;numTexte=137&#x00026;pageDebut=01355&#x00026;pageFin=01355</ext-link></comment><ext-link ext-link-type="webcite" xlink:href="6GmUKScRz"/></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biffi</surname><given-names>M</given-names></name><name><surname>Ziacchi</surname><given-names>M</given-names></name><name><surname>Bertini</surname><given-names>M</given-names></name><name><surname>Sangiorgi</surname><given-names>D</given-names></name><name><surname>Corsini</surname><given-names>D</given-names></name><name><surname>Martignani</surname><given-names>C</given-names></name><name><surname>Diemberger</surname><given-names>I</given-names></name><name><surname>Boriani</surname><given-names>G</given-names></name></person-group><article-title>Longevity of implantable cardioverter-defibrillators: implications for clinical practice and health care systems</article-title><source>Europace</source><year>2008</year><month>11</month><volume>10</volume><issue>11</issue><fpage>1288</fpage><lpage>95</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europace.oxfordjournals.org/cgi/pmidlookup?view=long&#x00026;pmid=18772164"/></comment><pub-id pub-id-type="doi">10.1093/europace/eun240</pub-id><pub-id pub-id-type="medline">18772164</pub-id><!--<pub-id pub-id-type="pii">eun240</pub-id>--><pub-id pub-id-type="pmid">18772164</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biffi</surname><given-names>M</given-names></name><name><surname>Ziacchi</surname><given-names>M</given-names></name><name><surname>Bertini</surname><given-names>M</given-names></name><name><surname>Gardini</surname><given-names>B</given-names></name><name><surname>Mazzotti</surname><given-names>A</given-names></name><name><surname>Massaro</surname><given-names>G</given-names></name><name><surname>Martignani</surname><given-names>C</given-names></name><name><surname>Diemberger</surname><given-names>I</given-names></name><name><surname>Boriani</surname><given-names>G</given-names></name><name><surname>Corsini</surname><given-names>D</given-names></name></person-group><article-title>How to truly value implantable cardioverter-defibrillators technology: up-front cost or daily cost?</article-title><source>Int J Technol Assess Health Care</source><year>2011</year><month>7</month><volume>27</volume><issue>3</issue><fpage>201</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1017/S0266462311000183</pub-id><pub-id pub-id-type="medline">21756409</pub-id><!--<pub-id pub-id-type="pii">S0266462311000183</pub-id>--><pub-id pub-id-type="pmid">21756409</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kind</surname><given-names>P</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Brooks</surname><given-names>R</given-names></name><name><surname>Rabin</surname><given-names>R</given-names></name><name><surname>de Charro</surname><given-names>F</given-names></name></person-group><article-title>Guidelines for value sets in economicnon-economic studies using EQ-5D</article-title><source>The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective</source><year>2003</year><publisher-loc>Dordrecht, Netherlands</publisher-loc><publisher-name>Kluwer Academic Publishers</publisher-name></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>NH</given-names></name><name><surname>Edwards</surname><given-names>RT</given-names></name><name><surname>Linck</surname><given-names>P</given-names></name><name><surname>Muntz</surname><given-names>R</given-names></name><name><surname>Hibbs</surname><given-names>R</given-names></name><name><surname>Wilkinson</surname><given-names>C</given-names></name><name><surname>Russell</surname><given-names>I</given-names></name><name><surname>Russell</surname><given-names>D</given-names></name><name><surname>Hounsome</surname><given-names>B</given-names></name></person-group><article-title>Cost-utility analysis of osteopathy in primary care: results from a pragmatic randomized controlled trial</article-title><source>Fam Pract</source><year>2004</year><month>12</month><volume>21</volume><issue>6</issue><fpage>643</fpage><lpage>50</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://fampra.oxfordjournals.org/cgi/pmidlookup?view=long&#x00026;pmid=15531626"/></comment><pub-id pub-id-type="doi">10.1093/fampra/cmh612</pub-id><pub-id pub-id-type="medline">15531626</pub-id><!--<pub-id pub-id-type="pii">cmh612</pub-id>--><pub-id pub-id-type="pmid">15531626</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manca</surname><given-names>A</given-names></name><name><surname>Hawkins</surname><given-names>N</given-names></name><name><surname>Sculpher</surname><given-names>MJ</given-names></name></person-group><article-title>Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility</article-title><source>Health Econ</source><year>2005</year><month>5</month><volume>14</volume><issue>5</issue><fpage>487</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1002/hec.944</pub-id><pub-id pub-id-type="medline">15497198</pub-id><pub-id pub-id-type="pmid">15497198</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>JA</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group><article-title>Analysis and interpretation of cost data in randomised controlled trials: review of published studies</article-title><source>BMJ</source><year>1998</year><month>10</month><day>31</day><volume>317</volume><issue>7167</issue><fpage>1195</fpage><lpage>200</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/9794854"/></comment><pub-id pub-id-type="medline">9794854</pub-id><!--<pub-id pub-id-type="pmcid">PMC28702</pub-id>--><pub-id pub-id-type="pmid">9794854</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Barber</surname><given-names>JA</given-names></name></person-group><article-title>How should cost data in pragmatic randomised trials be analysed?</article-title><source>BMJ</source><year>2000</year><month>4</month><day>29</day><volume>320</volume><issue>7243</issue><fpage>1197</fpage><lpage>200</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://europepmc.org/abstract/MED/10784550"/></comment><pub-id pub-id-type="medline">10784550</pub-id><!--<pub-id pub-id-type="pmcid">PMC1127588</pub-id>--><pub-id pub-id-type="pmid">10784550</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klersy</surname><given-names>C</given-names></name><name><surname>De Silvestri</surname><given-names>A</given-names></name><name><surname>Gabutti</surname><given-names>G</given-names></name><name><surname>Raisaro</surname><given-names>A</given-names></name><name><surname>Curti</surname><given-names>M</given-names></name><name><surname>Regoli</surname><given-names>F</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name></person-group><article-title>Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure</article-title><source>Eur J Heart Fail</source><year>2011</year><month>4</month><volume>13</volume><issue>4</issue><fpage>450</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hfq232</pub-id><pub-id pub-id-type="medline">21193439</pub-id><!--<pub-id pub-id-type="pii">hfq232</pub-id>--><pub-id pub-id-type="pmid">21193439</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devlin</surname><given-names>N</given-names></name><name><surname>Parkin</surname><given-names>D</given-names></name></person-group><article-title>Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis</article-title><source>Health Econ</source><year>2004</year><month>5</month><volume>13</volume><issue>5</issue><fpage>437</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1002/hec.864</pub-id><pub-id pub-id-type="medline">15127424</pub-id><pub-id pub-id-type="pmid">15127424</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>GA</given-names></name><name><surname>Kaul</surname><given-names>S</given-names></name></person-group><article-title>Cost, effectiveness, and cost-effectiveness</article-title><source>Circ Cardiovasc Qual Outcomes</source><year>2009</year><month>1</month><volume>2</volume><issue>1</issue><fpage>49</fpage><lpage>54</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://circoutcomes.ahajournals.org/cgi/pmidlookup?view=long&#x00026;pmid=20031812"/></comment><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.108.793406</pub-id><pub-id pub-id-type="medline">20031812</pub-id><!--<pub-id pub-id-type="pii">2/1/49</pub-id>--><pub-id pub-id-type="pmid">20031812</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanaboni</surname><given-names>P</given-names></name><name><surname>Lettieri</surname><given-names>E</given-names></name></person-group><article-title>Institutionalizing telemedicine applications: the challenge of legitimizing decision-making</article-title><source>J Med Internet Res</source><year>2011</year><volume>13</volume><issue>3</issue><fpage>e72</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.jmir.org/2011/3/e72/"/></comment><pub-id pub-id-type="doi">10.2196/jmir.1669</pub-id><pub-id pub-id-type="medline">21955510</pub-id><!--<pub-id pub-id-type="pii">v13i3e72</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC3222171</pub-id>--><pub-id pub-id-type="pmid">21955510</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crossley</surname><given-names>GH</given-names></name><name><surname>Boyle</surname><given-names>A</given-names></name><name><surname>Vitense</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Mead</surname><given-names>RH</given-names></name><collab>CONNECT Investigators</collab></person-group><article-title>The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts</article-title><source>J Am Coll Cardiol</source><year>2011</year><month>3</month><day>8</day><volume>57</volume><issue>10</issue><fpage>1181</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.12.012</pub-id><pub-id pub-id-type="medline">21255955</pub-id><!--<pub-id pub-id-type="pii">S0735-1097(10)05068-0</pub-id>--><pub-id pub-id-type="pmid">21255955</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Par&#x000e9;</surname><given-names>G</given-names></name><name><surname>Moqadem</surname><given-names>K</given-names></name><name><surname>Pineau</surname><given-names>G</given-names></name><name><surname>St-Hilaire</surname><given-names>C</given-names></name></person-group><article-title>Clinical effects of home telemonitoring in the context of diabetes, asthma, heart failure and hypertension: a systematic review</article-title><source>J Med Internet Res</source><year>2010</year><volume>12</volume><issue>2</issue><fpage>e21</fpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.jmir.org/2010/2/e21/"/></comment><pub-id pub-id-type="doi">10.2196/jmir.1357</pub-id><pub-id pub-id-type="medline">20554500</pub-id><!--<pub-id pub-id-type="pii">v12i2e21</pub-id>--><!--<pub-id pub-id-type="pmcid">PMC2956232</pub-id>--><pub-id pub-id-type="pmid">20554500</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauchier</surname><given-names>L</given-names></name><name><surname>Sadoul</surname><given-names>N</given-names></name><name><surname>Kouakam</surname><given-names>C</given-names></name><name><surname>Briand</surname><given-names>F</given-names></name><name><surname>Chauvin</surname><given-names>M</given-names></name><name><surname>Babuty</surname><given-names>D</given-names></name><name><surname>Clementy</surname><given-names>J</given-names></name></person-group><article-title>Potential cost savings by telemedicine-assisted long-term care of implantable cardioverter defibrillator recipients</article-title><source>Pacing Clin Electrophysiol</source><year>2005</year><month>1</month><volume>28 Suppl 1</volume><fpage>S255</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8159.2005.00071.x</pub-id><pub-id pub-id-type="medline">15683509</pub-id><!--<pub-id pub-id-type="pii">PACE071</pub-id>--><pub-id pub-id-type="pmid">15683509</pub-id></element-citation></ref></ref-list></back></article>